Emedastine

Emedastine
Systematic (IUPAC) name
1-(2-ethoxyethyl)-2-(4-methyl-1,4-diazepan-1-yl)-benzimidazole
Clinical data
Trade names Emadine
AHFS/Drugs.com monograph
Routes of
administration
Topical (ophthalmic solution)
Legal status
  • (Prescription only)
Pharmacokinetic data
Bioavailability ~50% (oral) (Tmax = 1–2 hours)[1]
Metabolism Hepatic
Biological half-life 3–4 hours (oral), 10 hours (topical)
Identifiers
CAS Number 87233-61-2 YesY
ATC code S01GX06 (WHO)
PubChem CID 3219
IUPHAR/BPS 7174
DrugBank DB01084 YesY
ChemSpider 3106 YesY
UNII 9J1H7Y9OJV YesY
KEGG D07890 YesY
ChEBI CHEBI:4779 YesY
ChEMBL CHEMBL594 YesY
Chemical data
Formula C17H26N4O
Molar mass 302.415 g/mol
  (verify)

Emedastine (trade name Emadine) is a second generation antihistamine used in eye drops to alleviate the symptoms of allergic conjunctivitis. It acts as a H1 receptor antagonist. It works by blocking the action of histamine that causes allergic symptoms. It is used in form of the difumarate.[2] The formation of emedastine difumarate is a white, crystalline, water-soluble fine powder. Emedasine is applied as an eye drop with 2 times a day. When the patients with allergic conjunctivitis were treated with 0.05% emedastin difumarate ophthalmic solution for six weeks, the signs and symptoms such as redness, itching and swelling of the eyes were relieved. Emedastine appears to be devoid of effects on adrenergic, dopaminergic and serotonin receptors. This drug was developed by alcon which is global medical company specializing in eye care products.

Pharmacodynamics

Emedastine is significantly selective to H1 histamine receptors (Ki = 1.3 nM), whereas its affinities for other histamine receptors were low (H2: Ki = 49067 nM and H3: Ki = 12430 nM) ub in vitro study. Topical ocular administration of emedastine inhibits histamine-stimulated vascular permeability in the conjunctiva as a concentration-dependent manner in in vitro study.

Pharmacokinetics

The human oral bioavailability is approximately 50% and maximum plasma concentration was achieved within 1–2 hours after dosing. Emedastine is mainly metabolized by the liver. There are two primary metabolites: 5-hydroxyemedastine and 6-hydroxyemedastine. They are excreted in the urine as both free and conjugated forms. The 5'-oxoanalogs of 5-hydroxyemedastine, 6-hydroxyemedastine and the N-oxide are also formed as minor metabolites. The elimination half-life of oral emedastine in plasma is 3–4 hours, whereas that of topical emedastine is 10 hours. Approximately 44% of the oral dose is recovered in the urine over 24 hours with only 3.6% of the dose excreted as parent drug.[1]

Contraindications

Emedastine should not be used in patients who are hypersensitive to any other ingredients or emedastine. Benzalkonium chloride contained in the bottle of emedastine solution can discolor soft contact lenses, so people who wear contact lenses should be careful using it.

Adverse events

The most common adverse effect was headache (11%). The other minor adverse effects encountered in less than 5% of patients were asthenia, burning or stinging sensation, unpleasant taste, blurred vision, eye dryness and tearing.

References

  1. 1 2 "Emadine (emedastine difumarate ophthalmic solution) 0.05%. Full Prescribing Information" (PDF). Alcon Laboratories, Inc. 6201 South Freeway Fort Worth, Texas 76134, USA. Retrieved 5 January 2016.
  2. Bielory, L.; Lien, K. W.; Bigelsen, S. (2005). "Efficacy and tolerability of newer antihistamines in the treatment of allergic conjunctivitis". Drugs 65 (2): 215–228. doi:10.2165/00003495-200565020-00004. PMID 15631542.
This article is issued from Wikipedia - version of the Saturday, April 02, 2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.